Alibaba Cloud Expands Offerings for EMEA Partners
Alibaba Cloud, the cloud computing and data intelligence arm of Alibaba Group, today announced that an additional nine partners have joined its EMEA Ecosystem Partner Program. Introduced last year, the program was developed to strengthen the collaboration between Alibaba Cloud’s customers and partners in Europe, Middle East and Africa. Alibaba Cloud has also furthered its commitment in nurturing young talents in cloud computing and big data by partnering with French local universities. The announcements were made at Alibaba Cloud Partner Summit, held during the VivaTech show in Paris.
The new partners on board of the program include Cloud Temple, Equinix, EVA Group, Groupe Cyllene, GTI Software & Networking, PROJIXI Europe, SKALE-5, SMILE, and Xebia. By partnering with Alibaba Cloud, together they can facilitate the digital transformation of companies in the EMEA region, especially those in the retail sector by leveraging Alibaba Group’s expertise in e-commerce, logistics and New Retail. Furthermore, the partners will be able to tap into the company’s business success and market insights in order to expand their presence in China under the “China Gateway” initiative.
“We believe in leveraging our partners’ strengths to create a strong ecosystem for technologies and solution offerings,” said Yeming Wang, General Manager, Alibaba Cloud EMEA. “By offering our state-of-the-art cloud infrastructure and advanced data intelligence services, together with our partners, we hope to accelerate companies’ digital transformation, and help them succeed globally in markets especially in China.”
Existing EMEA partners include companies such as Linkbynet, Ecritel, Micropole, and Intel who joined the program last year. They were not alone in identifying the benefits of partnering with Alibaba Cloud; Gartner named Alibaba Cloud third globally for IaaS (Infrastructure as a Service) and IUS (Infrastructure Utility Services), and the first in Asia Pacific in the same space.
With an eye to nurturing future workplace talent, Alibaba Cloud has also teamed up with local universities in France. In addition to partnering with Telecom ParisTech last year to introduce cloud computing and big data training for its students, this year, Alibaba Cloud announced its partnership with SUPINFO International University, institute of information technology and computer sciences created in Paris in 1965 and with over 30 campuses worldwide. The parties will collaborate closely on matters relating to course design, certification training, IT infrastructure building and cross border connectivity.
“We are pleased to partner with Alibaba Cloud to have our students equipped with useful knowledge on cloud computing technologies, especially in its applications. We believe in empowering students through learning and together with Alibaba Cloud, we can bring the best designed practical courses to them. We want to offer a rich technology test bed for students to experiment different skills in order to prepare them to solve real-life challenges upon graduation,” said Alick MOURIESSE, President of SUPINFO International University.
“Through the collaborations with local universities, Alibaba Cloud can bring our knowledge in cloud computing, big data and artificial intelligence to students in France, which is essential to improving their competitive advantages in the workplace,” said Kevin Liu, Country Manager, Alibaba Cloud France & South Europe. “The partnership with SUPINFO following the tie up with Telecom ParisTech further demonstrated our commitment to France and our contributions to talent development.”
In addition to its presence at VivaTech in France, Alibaba Cloud will also host its Partner Summit in UK and Germany, with the aim of attracting more participants to its EMEA Ecosystem Partner Program.
About Alibaba Cloud
Established in 2009, Alibaba Cloud (www.alibabacloud.com), the cloud computing and data intelligence arm of Alibaba Group, is among the world’s top three IaaS providers, according to Gartner, and the largest provider of public cloud services in China, according to IDC. Alibaba Cloud provides a comprehensive suite of cloud computing services to businesses worldwide, including merchants doing business on Alibaba Group marketplaces, start-ups, corporations and government organizations. Alibaba Cloud is the official Cloud Services Partner of the International Olympic Committee.
View source version on businesswire.com: https://www.businesswire.com/news/home/20190516006168/en/
Contact information
Claudia JU
+86 571 8656 1860
Claudia.ju@alibaba-inc.com
Crystal Liu
+86 18578497650
Crystal.liu@alibaba-inc.com
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
FDA Approves OTEZLA® (apremilast) for the Treatment of Oral Ulcers Associated with Behçet’s Disease19.7.2019 20:59:00 EEST | Press release
Celgene Corporation (NASDAQ:CELG) today announced that the U.S. Food and Drug Administration (FDA) has approved OTEZLA® (apremilast) 30 mg twice daily (BID) for the treatment of adult patients with oral ulcers associated with Behçet’s Disease. OTEZLA, an oral, selective inhibitor of phosphodiesterase 4 (PDE4), is the first and only approved treatment option for oral ulcers associated with Behçet’s Disease, a rare, chronic, multisystem inflammatory disease that is difficult to treat. “Oral ulcers are a recurring and debilitating manifestation that affects nearly everyone living with Behçet’s Disease, and have an important negative impact on the quality of life for these patients,” said Yusuf Yazici, M.D., Clinical Associate Professor, Department of Medicine, New York University Langone Health. “In the clinical trial, OTEZLA demonstrated improvements in measures of oral ulcers at week 12. OTEZLA has the potential to be a needed treatment option for U.S. patients and their physicians, who
Abiraterone Acetate Included in World Health Organisation’s Essential Medicines List for the Treatment of Metastatic Castration-Resistant Prostate Cancer19.7.2019 16:05:00 EEST | Press release
The Janssen Pharmaceutical Companies of Johnson & Johnson is delighted with the recent announcement from the World Health Organisation (WHO) to include abiraterone acetate (ZYTIGA ® ) for the treatment of metastatic castration-resistant prostate cancer (mCRPC), in the updated Essential Medicines List, published on 9th July 2019.1,2 The WHO’s Essential Medicines List is a core guidance document that helps countries prioritise critical health products that are recommended to be widely available and affordable throughout health systems.1 “The inclusion of abiraterone acetate in the WHO Essential Medicines List highlights the critical role that this treatment can play in improving the lives of patients living with mCRPC and their families,” said Dr. Joaquín Casariego, Janssen Therapeutic Area Lead Oncology for Europe, Middle East & Africa, Janssen-Cilag S.A. “I am proud that we are working hard to impact survival and quality of life by developing and providing innovative medicines which ar
Gilead Sciences Licenses Respiratory and Herpes Antiviral Research Programs From Novartis19.7.2019 15:30:00 EEST | Press release
Gilead Sciences, Inc. (NASDAQ: GILD) announced today that it has licensed three preclinical antiviral programs from Novartis, including investigational agents with the potential to treat human rhinovirus, influenza and herpes viruses. Under the agreement, Gilead will acquire exclusive global rights to develop and commercialize novel small molecules against three undisclosed targets. Novartis will receive an upfront payment and is eligible to receive up to an additional $291 million in potential milestone payments upon achievement of certain development and commercial milestones, as well as royalties on annual net sales. “Today’s announcement builds on Gilead’s heritage in antiviral research and development. We look forward to applying this expertise to advance the development of potential new treatments for viruses with limited therapeutic options,” said John McHutchison AO, MD, Gilead’s Chief Scientific Officer and Head of Research and Development. Gilead’s antiviral portfolio include
Schlumberger Announces Second-Quarter 2019 Results19.7.2019 14:00:00 EEST | Press release
Schlumberger Limited (NYSE: SLB) today reported results for the second quarter of 2019. (Stated in millions, except per share amounts) Three Months Ended Change Jun. 30, 2019 Mar. 31, 2019 Jun. 30, 2018 Sequential Year-on-year Revenue $8,269 $7,879 $8,303 5% 0% Pretax segment operating income $968 $908 $1,094 7% -12% Pretax segment operating margin 11.7% 11.5% 13.2% 17 bps -148 bps Net income - GAAP basis $492 $421 $430 17% 14% Net income, excluding charges & credits* $492 $421 $594 17% -17% Diluted EPS - GAAP basis $0.35 $0.30 $0.31 17% 13% Diluted EPS, excluding charges & credits* $0.35 $0.30 $0.43 17% -19% North America revenue $2,801 $2,738 $3,139 2% -11% International revenue $5,463 $5,037 $5,065 8% 8% North America revenue, excluding Cameron $2,243 $2,178 $2,546 3% -12% International revenue, excluding Cameron $4,761 $4,469 $4,387 7% 9% *These are non-GAAP financial measures. See section titled "Charges & Credits" for details. Schlumberger Chairman and CEO Paal Kibsgaard commente
Schlumberger Appoints Olivier Le Peuch as CEO19.7.2019 13:46:00 EEST | Press release
Schlumberger Limited (NYSE: SLB) announced today that its Board of Directors has appointed Olivier Le Peuch as its Chief Executive Officer and member of the Schlumberger Board, effective August 1, 2019. Mr. Le Peuch succeeds Paal Kibsgaard, who will retire as Chief Executive Officer effective that same date. Also effective August 1, Mr. Kibsgaard will step down as Chairman of the Board and retire as a member of the Board of Directors. Mr. Kibsgaard will retire after more than 22 years of service to the Company, including eight years as CEO and four years as Chairman. Effective the same date, Mark G. Papa, a current non-independent director, will become non-executive Chairman of the Board. Peter Currie will continue to serve as the Board’s Lead Independent Director. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20190719005161/en/ Olivier Le Peuch is appointed Chief Executive Officer and a member of the Schlumberger Board, effe
Fluke Corporation Acquires Industrial Reliability Leader PRÜFTECHNIK19.7.2019 13:00:00 EEST | Press release
Fluke Corp., the global leader in test and measurement instruments, has acquired Ismaning, Germany-based PRÜFTECHNIK, a market leader in precision laser shaft alignment, condition monitoring, and non-destructive testing. “Fluke’s acquisition of PRÜFTECHNIK reflects the growing importance our customers place on reliability systems to keep their equipment in optimum operating condition,” said Marc Tremblay, president of Fluke Corporation. “This business will help us usher in the next generation of solutions for our industrial customers.” Fluke Corporation For information on Fluke tools and applications, or to find the location of your nearest distributor, contact Fluke Corporation, P.O. Box 9090, Everett, WA USA 98206, call (800) 44-FLUKE (800-443-5853), fax (425) 446-5116, e-mail fluke-info@fluke.com or visit the Fluke Web site at http://www.fluke.com. About Fluke Founded in 1948, Fluke Corporation is the world leader in compact, professional electronic test tools and software for measu
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom